PTRF/Cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Gámez Pozo, Angelo ^a   Sánchez Navarro, Iker ^a   Calvo, Enrique ^b   Agulló Ortuño, María Teresa ^c   López Vacas, Rocío ^a   Díaz, Esther ^a   Camafeita, Emilio ^b   Nistal, Manuel ^d   Madero, Rosario ^d   Espinosa, Enrique ^a   López, Juan Antonio ^b   Vara, Juan Ángel Fresno ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PHOSPHOPEPTIDE; PHOSPHOPROTEIN; PROTEIN CAVIN 1; PROTEIN MIF; TUMOR PROTEIN; UNCLASSIFIED DRUG; ISOMERASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MIF PROTEIN, HUMAN; PTRF PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

ARTICLE; BIOINFORMATICS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEOMICS; WESTERN BLOTTING; AMINO ACID SEQUENCE; BIOLOGICAL MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; LUNG; LUNG TUMOR; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; PATHOLOGY; REPRODUCIBILITY;

AMINO ACID SEQUENCE; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAMOLECULAR OXIDOREDUCTASES; LUNG; LUNG NEOPLASMS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MASS SPECTROMETRY; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; PHOSPHOPEPTIDES; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84858844311     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033752     Document Type: Article

References (50)

1. Mountain CF, (1997) Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717.
2. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827.
3. Groseclose MR, Massion PP, Chaurand P, Caprioli RM, (2008) High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 8: 3715-3724.
4. Conrad DH, Goyette J, Thomas PS, (2008) Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 23 (Suppl 1): 78-84.
5. Hanash S, (2003) Disease proteomics. Nature 422: 226-232.
6. Marko-Varga G, Ogiwara A, Nishimura T, Kawamura T, Fujii K, et al. (2007) Personalized medicine and proteomics: lessons from non-small cell lung cancer. J Proteome Res 6: 2925-2935.
7. Pastwa E, Somiari SB, Czyz M, Somiari RI, (2007) Proteomics in human cancer research. Proteomics Clin Appl 1: 4-17.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
9. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM, (2001) Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 7: 493-496.
10. Cohen P, (2002) Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1: 309-315.
11. Gamez-Pozo A, Sanchez-Navarro I, Nistal M, Calvo E, Madero R, et al. (2009) MALDI profiling of human lung cancer subtypes. PLoS One 4: e7731.
12. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
13. Huang DW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
14. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, et al. (2003) PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 13: 2129-2141.
15. Cho RJ, Campbell MJ, (2000) Transcription, genomes, function. Trends Genet 16: 409-415.
16. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, et al. (2009) STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37: D412-416.
17. Bodenmiller B, Mueller LN, Mueller M, Domon B, Aebersold R, (2007) Reproducible isolation of distinct, overlapping segments of the phosphoproteome. Nat Methods 4: 231-237.
18. Aryal UK, Ross AR, (2010) Enrichment and analysis of phosphopeptides under different experimental conditions using titanium dioxide affinity chromatography and mass spectrometry. Rapid Commun Mass Spectrom 24: 219-231.
19. Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, et al. (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20: 1630-1639.
20. Jensen SS, Larsen MR, (2007) Evaluation of the impact of some experimental procedures on different phosphopeptide enrichment techniques. Rapid Commun Mass Spectrom 21: 3635-3645.
21. Han G, Ye M, Zhou H, Jiang X, Feng S, et al. (2008) Large-scale phosphoproteome analysis of human liver tissue by enrichment and fractionation of phosphopeptides with strong anion exchange chromatography. Proteomics 8: 1346-1361.
22. Sugiyama N, Masuda T, Shinoda K, Nakamura A, Tomita M, et al. (2007) Phosphopeptide enrichment by aliphatic hydroxy acid-modified metal oxide chromatography for nano-LC-MS/MS in proteomics applications. Mol Cell Proteomics 6: 1103-1109.
23. Nagaraj N, D'Souza RC, Cox J, Olsen JV, Mann M, (2010) Feasibility of large-scale phosphoproteomics with higher energy collisional dissociation fragmentation. J Proteome Res 9: 6786-6794.
24. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
25. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, et al. (2010) The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer. J Thorac Oncol 6: 824-833.
26. Ciardiello F, Tortora G, (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
27. Gazdar AF, (2010) Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev 29: 37-48.
28. Ray M, Salgia R, Vokes EE, (2009) The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 14: 1116-1130.
29. Mitchell RA, (2004) Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16: 13-19.
30. Lee H, Rhee H, Kang HJ, Kim HS, Min BS, et al. (2008) Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol 129: 772-779.
31. Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, et al. (2007) Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 282: 29910-29918.
32. Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, et al. (2009) The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 115: 2031-2040.
33. McClelland M, Zhao L, Carskadon S, Arenberg D, (2009) Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am J Pathol 174: 638-646.
34. Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, et al. (2008) A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res 68: 7253-7257.
35. Garai J, Lorand T, (2009) Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: current developments. Curr Med Chem 16: 1091-1114.
36. Jansa P, Grummt I, (1999) Mechanism of transcription termination: PTRF interacts with the largest subunit of RNA polymerase I and dissociates paused transcription complexes from yeast and mouse. Mol Gen Genet 262: 508-514.
37. Hill MM, Bastiani M, Luetterforst R, Kirkham M, Kirkham A, et al. (2008) PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 132: 113-124.
38. Cohen AW, Hnasko R, Schubert W, Lisanti MP, (2004) Role of caveolae and caveolins in health and disease. Physiol Rev 84: 1341-1379.
39. Aboulaich N, Ortegren U, Vener AV, Stralfors P, (2006) Association and insulin regulated translocation of hormone-sensitive lipase with PTRF. Biochem Biophys Res Commun 350: 657-661.
40. Hayashi YK, Matsuda C, Ogawa M, Goto K, Tominaga K, et al. (2009) Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest 119: 2623-2633.
41. Aboulaich N, Vainonen JP, Stralfors P, Vener AV, (2004) Vectorial proteomics reveal targeting, phosphorylation and specific fragmentation of polymerase I and transcript release factor (PTRF) at the surface of caveolae in human adipocytes. Biochem J 383: 237-248.
42. Liu L, Pilch PF, (2008) A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem 283: 4314-4322.
43. Bai L, Deng X, Li J, Wang M, Li Q, et al. (2011) Regulation of cellular senescence by the essential caveolar component PTRF/Cavin-1. Cell Res 21: 1088-1101.
44. Volonte D, Galbiati F, (2011) Polymerase I and transcript release factor (PTRF)/cavin-1 is a novel regulator of stress-induced premature senescence. J Biol Chem 286: 28657-28661.
45. Zhu H, Lin P, De G, Choi KH, Takeshima H, et al. (2011) Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair. J Biol Chem 286: 12820-12824.
46. Gould ML, Williams G, Nicholson HD, (2010) Changes in caveolae, caveolin, and polymerase 1 and transcript release factor (PTRF) expression in prostate cancer progression. Prostate 70: 1609-1621.
47. Aung CS, Hill MM, Bastiani M, Parton RG, Parat MO, (2010) PTRF-cavin-1 expression decreases the migration of PC3 prostate cancer cells: role of matrix metalloprotease 9. Eur J Cell Biol 90: 136-142.
48. Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, et al. (2006) Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res 66: 11194-11206.
49. Bai L, Deng X, Li Q, An W, Deli A, et al. (2011) Down-regulation of the cavin family proteins in breast cancer. J Cell Biochem doi:10.1002/jcb.23358.
50. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, et al. (2008) Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A 105: 14112-14117.